# Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice

> **NCT05694013** · PHASE2,PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 49 (actual)

## Conditions studied

- Cancer

## Interventions

- **DEVICE:** Roche DPM Module
- **DRUG:** Atezolizumab SC
- **OTHER:** Local SOC support

## Key facts

- **NCT ID:** NCT05694013
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-02-27
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** Study terminated by sponsor.
- **Last updated:** 2025-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05694013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05694013, "Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05694013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*